N-Site is a portal for Life Sciences companies where you can find a range of technical guidance notes on legal and tax matters that impact the industry. Established by FTI Consulting in 2016 and developed in association with MedCity and the BioIndustry Association (BIA), the vision is that N-Site will become a primary resource for Expert Guidance for Life Sciences.
FTI Consulting’s European Tax Advisory practice comprises a wide range of leading industry specialisms one of which is a unique team supporting Life Sciences.
With a dedicated sector focus, FTI Consulting has been able to develop a number unique offerings for Life Sciences companies to support them in a range of tax matters including licensing, enhancing R&D tax reliefs, pharmaceutical transfer pricing and advanced tax modelling for financial forecasting.
Taylor Wessing is a leading international law firm, working with clients in the world’s most dynamic industries.
The Life Sciences sector lies at the heart of Taylor Wessing’s services. Their reputation is based on experience working across many practice areas essential to the sector internationally including:
- pharmaceutical and medical device patent litigation
- regulatory and competition work
- transactional licensing and collaboration work
- M&A, venture capital and capital markets
- International commercial litigation and arbitration
They have a 30+ year commitment and track record in the sector, advising and acting in relation to pharmaceutical, biotech, medical device, diagnostics and research tool products. With an enviable reputation in serving knowledge-based and technology-oriented businesses, their client-focused, multi-disciplinary approach has resulted in the Life Sciences Group and its members being described as “outstanding”, “leading authorities”, “acknowledged experts”, and “highly rated” in the latest editions of independent directories such as Chambers, PLC Global Counsel and Legal 500.
Taylor Wessing’s continually growing international client base also reflects the high repute in which they are held.
Their range of clients is diverse – from multi-national pharmaceutical ‘giants’ to biotech start-ups – and includes manufacturers of medical devices. Their multidisciplinary life sciences legal team works across 19 jurisdictions. It includes lawyers with degrees and PhDs in the biological sciences and many of our lawyers have in-house experience.
They look closely at your business objectives and work out how they can best support you in order to achieve them. Their practice is built on the belief that it is important to understand the scientific and business challenges facing companies in the life sciences sector and they take these into account in a practical and commercial way.
MedCity is a collaboration between the Mayor of London and the capital’s three Academic Health Science Centres – Imperial College Academic Health Science Centre, King’s Health Partners, and UCL Partners. Launched in April 2014 to promote and grow the UK’s world-leading life sciences clusters, it is promoting life sciences investment, entrepreneurship and industry in the region by:
- Providing a single front door and concierge service for industry and investors looking for partners, infrastructure and expertise
- Facilitating and supporting collaboration across all parts of the sector to turn innovations into commercial products and services
- Fostering an environment that supports and encourages entrepreneurialism
- Raising awareness globally of the region’s rich life sciences ecosystem
It is supported by the Higher Education Funding Council for England and the Mayor of London and works with academics, research and NHS institutions, as well as local enterprise partnerships and the Mayor’s official promotional organisation London & Partners.
BioIndustry Association (BIA)
The BIA is the trade association for innovative enterprises involved in UK bioscience. BIA’s goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.
BIA’s members are responsible for over 90% of biotech medicines currently in clinical development in the UK. In the last year, BIA members have taken forward pioneering research such as the first stem cell therapy clinical trials for stroke and the first drug to delay bone metastases in cancer.
The BIA pushes for progress in UK bioscience on every front. Their goal is to deliver the best possible environment for growth and innovation.
Register to receive up-to-date information and advice on tax and law developments within your industry.